2022 Refresher - Gynecological
This educational activity will address the recent knowledge acquired in endometrial cancer mainly the indications for adjuvant RT and chemotherapy and the role of concurrent chemoradiation in high risk and locally advanced disease as well as the optimal sequencing approach when both modalities are used. In addition, the interpretation and potential impact of molecular markers will be discussed given the recent publication of the European guidelines which based their recommendations on molecular markers. Last, the interpretation and optimal management of sentinel LN biopsy and isolated tumor cells findings will be addressed.
This session will focus on providing updates in the management of cervical cancer. It will focus on the use of modern imaging and treatment techniques which are rapidly being adopted. This will include discussions of intensity modulated radiation therapy in the post-operative and definitive settings as well as how to integrate image guided adaptive brachytherapy. In addition we will review updated guidelines for target and organ at risk suggested doses for definitive cervical cancer treatment.
The activity is designed to meet the interests of radiation oncologists and radiation oncology residents, medical oncologists, surgeons, nurses and pathologists.
Upon completion of this live activity, attendees should be able to do the following:
- Determine the indications for systemic therapy and radiation therapy in non-metastatic endometrial cancer.
- Determine the appropriate sequencing approach for adjuvant chemotherapy and radiation.
- Explain the role of molecular markers and their potential impact on adjuvant therapy.
- Interpret the significance and interpretation of sentinel LN biopsy and isolated tumor cells in LN.
- Describe the rationale and evidence for image guided adaptive brachytherapy.
- Identify appropriate organ at risk dose constraints for image guided adaptive brachytherapy.
- Discuss recommended contouring guidelines for intensity modulated pelvic radiation therapy.
Lara Hathout, MD, FRCPC is employed by Rutgers Cancer Institute of New Jersey and has no financial relationships with a commercial interest.
Micthell Kamrava, MD is employed by Cedars Sinai Medical Center and has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.